Understanding, Preventing, and Managing Immunotherapy-related Adverse Events
The American Cancer Society and the Melanoma Research Alliance have partnered to support research leading towards reduction of immune-related adverse events and improvement of overall outcomes for cancer patients treated with checkpoint immunotherapy. This request for applications offers funding for grants to test feasibility and generate preliminary data in the form of Pilot Awards and at least one Multidisciplinary Team Award. The Melanoma Research Alliance and American Cancer Society have each committed $1 million, which will be used to fund at least one Multidisciplinary Team Award at $1 million for up to three years and up to five pilot awards at $200,000 each for two-year periods. Team Awards are designed to foster interdisciplinary collaborative research to promote transformational advances with the potential for rapid clinical benefit. Pilot Awards are intended to help seed the ground in this relatively young area of checkpoint immune-related adverse events research.
Team Award Eligibility: The Lead PI, Team Principals and Team Investigators must hold a doctorate degree (MD, PhD, or equivalent), be independent and have a full-time faculty position or equivalent at a college, university, medical school, or other fiscally responsible not-for-profit research organization within the United States. There are no citizenship restrictions. Multiple PIs or Co-PIs are not allowed. Early Career Team Investigators within the first 5 years of initial faculty appointment may serve as a Team Investigator. Early Career Team Investigators may not serve as the Lead PI.
Pilot Award Eligibility: Independent investigators at all stages of their career are eligible to apply. Principal investigators(PI) must hold a doctorate degree (MD, PhD, or equivalent) and have a full-time faculty position or equivalent at a college, university, medical school, or other not-for-profit organization within the United States. Multiple PIs or Co-PIs are not allowed.
Electronic Application Due Date: October 31, 2017
Paper Application Copy Due Date: November 1, 2017
Melanoma Research Alliance Awards
The Melanoma Research Alliance supports both individual investigator and collaborative team projects focused on translational, innovative research that will impact the prevention, diagnosis, staging, and treatment of melanoma in the near and intermediate future. Current funding opportunities include:
- Young Investigator Awards for Women in Scientific Research support early career female researchers who are conducting cutting-edge melanoma research. The awardee will receive up to $225,000 total over three years to support projects with the potential to lead to transformative advances in prevention, detection, diagnosis, staging or treatment of melanoma. For this award, the PI must be a woman.
- Young Investigator Awards support early career scientists with novel ideas into the field of melanoma, thereby recruiting and supporting the next generation of melanoma research leaders. Awardees will be provided up to $75,000 per year for three years (up to $225,000 total) to accomplish innovative and creative, preclinical, translational, and/or early clinical research projects.
- Established Investigator Awards support senior investigators with a record of scientific productivity and accomplishment and who are past the initial four years of their first academic faculty appointment. Investigators with an established record of scientific productivity will receive up to $100,000 per year for two to three years (up to $300,000 total) from MRA to conduct projects supported by preliminary data.
Application Due Date: November 17, 2017
ASCO Resident Travel Award for Underrepresented Populations
The Conquer Cancer Foundation of ASCO Resident Travel Award for Underrepresented Populations provides financial support for residents from underrepresented populations to attend ASCO’s Annual Meeting. This award allows physician residents interested in a career in oncology to travel to the ASCO Annual Meeting, where they will have the opportunity to meet oncologists and to learn more about career option in the field of oncology. The award includes a $1,500 travel advance and complimentary ASCO Annual Meeting registration. The number of Resident Travel Awards in each funding cycle is not predetermined by the Conquer Cancer Foundation. Awards are given based on individual merit and availability of funds.
Application Due Date: December 1, 2017
Alex's Lemonade Stand - Epidemiology Grants
Alex’s Lemonade Stand Epidemiology Grants are $100,000 per year for two years. Funding allows investigators to pursue research studies in human populations, using epidemiological approaches, in order to significantly contribute to the understanding of childhood cancers. Hypothesis-driven research may focus on risk factors, early detection, prevention, effectiveness and treatment outcomes. Awards are $100,000 per year for two years.
Application Due Date: December 15, 2017
NCI Clinical and Translational Exploratory/Developmental Studies (R21)
The National Cancer Institute has issued this funding opportunity to promote innovative pre-clinical, early-phase clinical, and correlative studies that are hypothesis-driven and based upon established basic cancer research discoveries. By using the R21 mechanism, this funding opportunity will support exploratory/developmental projects in the advancement of novel anti-cancer agents, diagnostic tools, and clinical approaches in treatment, symptom management, and prevention of common or rare tumors. These studies may involve considerable risk, but may lead to a breakthrough in a particular area, and/or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of cancer research (pre-clinical or clinical).
Application Due Date: February 20, 2018
Paul Calabresi Career Development Award for Clinical Oncology (K12)
This funding opportunity announcement encourages applications for institutional research career development (K12) programs from applicant organizations that propose to promote the training and career development of clinical trials researchers. It is intended to increase the number of clinicians (MDs, DOs, PharmDs, nurses with PhDs or equivalent) and non-clinician postdoctoral researchers trained to design and test clinical therapeutic research protocols in clinical trial settings (pilot/Phase I, Phase II, and Phase III clinical trials).Application Due Date: June 15, 2018
Oral Anticancer Agents: Utilization, Adherence, and Health Care Delivery
The Behavioral Research Program, Epidemiology and Genomics Research Program, and Healthcare Delivery Research Program of the National Cancer Institute’s Division of Cancer Control and Population Sciences have collaborated on the release of a program announcement to study the utilization, adherence, and delivery of oral anticancer agents. Specifically, this program announcement encourages research grant applications to:
- Assess and describe the current state of oral anticancer medication utilization, delivery, and adherence;
- Identify structural, systemic, and psychosocial barriers to adherence; and
- Develop models and strategies to improve safe and effective delivery of these agents so that clinical outcomes are optimized.